301 related articles for article (PubMed ID: 34366231)
21. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
[TBL] [Abstract][Full Text] [Related]
22. Concomitant vancomycin and piperacillin/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients.
Haruki Y; Hagiya H; Haruki M; Inoue Y; Sugiyama T
J Infect Chemother; 2020 Oct; 26(10):1026-1032. PubMed ID: 32561128
[TBL] [Abstract][Full Text] [Related]
23. A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin-tazobactam versus vancomycin cefepime.
Elliott BP; Tang MM; Madden JA; Markert RJ; Burdette SD; Pleiman CM; Speelmon EC
Intern Emerg Med; 2022 Jan; 17(1):91-99. PubMed ID: 34089468
[TBL] [Abstract][Full Text] [Related]
24. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy.
Kim T; Kandiah S; Patel M; Rab S; Wong J; Xue W; Easley K; Anderson AM
BMC Res Notes; 2015 Oct; 8():579. PubMed ID: 26476979
[TBL] [Abstract][Full Text] [Related]
26. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.
Triffault-Fillit C; Mabrut E; Corbin K; Braun E; Becker A; Goutelle S; Chaudier P; Fessy MH; Dupieux C; Laurent F; Gunst S; Lustig S; Chidiac C; Ferry T; Valour F
J Antimicrob Chemother; 2020 Aug; 75(8):2299-2306. PubMed ID: 32407512
[TBL] [Abstract][Full Text] [Related]
27. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
[TBL] [Abstract][Full Text] [Related]
28. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis.
Giuliano CA; Patel CR; Kale-Pradhan PB
Pharmacotherapy; 2016 Dec; 36(12):1217-1228. PubMed ID: 27805728
[TBL] [Abstract][Full Text] [Related]
29. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
[TBL] [Abstract][Full Text] [Related]
30. Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.
Workum JD; Kramers C; Kolwijck E; Schouten JA; de Wildt SN; Brüggemann RJ
J Antimicrob Chemother; 2021 Jan; 76(1):212-219. PubMed ID: 32944771
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
32. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Alosaimy S; Lagnf AM; Hobbs ALV; Mubarez M; Kufel WD; Morrisette T; Polisetty RS; Li D; Veve MP; Simon SP; Truong J; Finch N; Venugopalan V; Rico M; Amaya L; Yost C; Cubillos A; Chandler E; Patch M; Smith IMK; Biagi M; Wrin J; Moore WJ; Molina KC; Rebold N; Holger D; Kunz Coyne AJ; Jorgensen SCJ; Witucki P; Tran NN; Davis SL; Sakoulas G; Rybak MJ
Clin Infect Dis; 2023 Feb; 76(3):e1444-e1455. PubMed ID: 35982631
[TBL] [Abstract][Full Text] [Related]
33. Risk of Acute Kidney Injury in Combat-Injured Patients Associated With Concomitant Vancomycin and Extended-Spectrum β-Lactam Antibiotic Use.
Yabes JM; Stewart L; Shaikh F; Robben PM; Petfield JL; Ganesan A; Campbell WR; Tribble DR; Blyth DM
J Intensive Care Med; 2021 Jul; 36(7):818-827. PubMed ID: 32508215
[TBL] [Abstract][Full Text] [Related]
34. Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER.
Ide N; Sako KI; Takigawa M; Tanaka H
In Vivo; 2024; 38(3):1436-1442. PubMed ID: 38688650
[TBL] [Abstract][Full Text] [Related]
35. Risk Factors for Teicoplanin-Associated Acute Kidney Injury in Patients with Hematological Malignancies: Focusing on Concomitant Use of Tazobactam/Piperacillin.
Morinaga Y; Tanaka R; Tatsuta R; Takano K; Hashimoto T; Ogata M; Hiramatsu K; Itoh H
Biol Pharm Bull; 2024; 47(5):988-996. PubMed ID: 38763761
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
37. Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: An open-label, placebo-controlled, randomized clinical trial.
Khalili H; Rahmani H; Mohammadi M; Salehi M; Mostafavi Z
Daru; 2021 Dec; 29(2):341-351. PubMed ID: 34463929
[TBL] [Abstract][Full Text] [Related]
38. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
[TBL] [Abstract][Full Text] [Related]
39. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Anderson CW; Cazares KS; Lustik MB; Patel SM; Denunzio TM
Mil Med; 2017 Sep; 182(9):e1773-e1778. PubMed ID: 28885936
[TBL] [Abstract][Full Text] [Related]
40. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
LeCleir LK; Pettit RS
Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
